Beneficial role of overexpression of TFPI‐2 on tumour progression in human small cell lung cancer

Lavergne, Marion; Jourdan, Matthieu; Bléchet, Claire; Guyétant, Serge; Pape, Alain Le; Heuzé-Vourc’h, Nathalie; Courty, Yves; Lerondel, Stéphanie; Sobilo, Julien; Iochmann, Sophie; Reverdiau, Pascale

doi:10.1016/j.fob.2013.06.004

Cited by 24 publications

(17 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CNN3 is involved in the regulation of cell migration and the placentation process . TFPI2 encodes a Kunitz‐type serine proteinase inhibitor with inhibitory function against tumor growth and metastasis; protecting the extracellular matrix of cancer cells from degradation and tumor invasion . COL17A1 encodes collagen XVII (COL17), a transmembrane protein that is an essential component of type I hemidesmosomes and acts as a cell‐matrix adhesion molecule .…”

Section: Discussionmentioning

confidence: 99%

Establishment of a novel experimental model for muscle‐invasive bladder cancer using a dog bladder cancer organoid culture

et al. 2019

View full text Add to dashboard Cite

In human and dogs, bladder cancer (BC) is the most common neoplasm affecting the urinary tract. Dog BC resembles human muscle‐invasive BC in histopathological characteristics and gene expression profiles, and could be an important research model for this disease. Cancer patient‐derived organoid culture can recapitulate organ structures and maintains the gene expression profiles of original tumor tissues. In a previous study, we generated dog prostate cancer organoids using urine samples, however dog BC organoids had never been produced. Therefore we aimed to generate dog BC organoids using urine samples and check their histopathological characteristics, drug sensitivity, and gene expression profiles. Organoids from individual BC dogs were successfully generated, expressed urothelial cell markers (CK7, CK20, and UPK3A) and exhibited tumorigenesis in vivo. In a cell viability assay, the response to combined treatment with a range of anticancer drugs (cisplatin, vinblastine, gemcitabine or piroxicam) was markedly different in each BC organoid. In RNA‐sequencing analysis, expression levels of basal cell markers (CK5 and DSG3) and several novel genes (MMP28, CTSE, CNN3, TFPI2, COL17A1, and AGPAT4) were upregulated in BC organoids compared with normal bladder tissues or two‐dimensional (2D) BC cell lines. These established dog BC organoids might be a useful tool, not only to determine suitable chemotherapy for BC diseased dogs but also to identify novel biomarkers in human muscle‐invasive BC. In the present study, for the 1st time, dog BC organoids were generated and several specifically upregulated organoid genes were identified. Our data suggest that dog BC organoids might become a new tool to provide fresh insights into both dog BC therapy and diagnostic biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishment of a novel experimental model for muscle‐invasive bladder cancer using a dog bladder cancer organoid culture

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Another upregulated gene, TFPI, an inhibitor of plasminactivating matrix metalloproteinases, blocks invasion and metastasis [30]. Downregulation of some common genes such as ID1, ID3, and IDH1 in fisetin-treated HL60 cells could be responsible for its apoptotic effects as well.…”

Section: Discussionmentioning

confidence: 99%

The pleiotropic effects of fisetin and hesperetin on human acute promyelocytic leukemia cells are mediated through apoptosis, cell cycle arrest, and alterations in signaling networks

Adan

Baran

2015

Tumor Biol.

View full text Add to dashboard Cite

Fisetin and hesperetin, flavonoids from various plants, have several pharmaceutical activities including antioxidative, anti-inflammatory, and anticancer effects. However, studies elucidating the role and the mechanism(s) of action of fisetin and hesperetin in acute promyelocytic leukemia are absent. In this study, we investigated the mechanism of the antiproliferative and apoptotic actions exerted by fisetin and hesperetin on human HL60 acute promyelocytic leukemia cells. The viability of HL60 cells was evaluated using the MTT assay, apoptosis by annexin V/propidium iodide (PI) staining and cell cycle distribution using flow cytometry, and changes in caspase-3 enzyme activity and mitochondrial transmembrane potential. Moreover, we performed wholegenome microarray gene expression analysis to reveal genes affected by fisetin and hesperetin that can be important for developing of future targeted therapy. Based on data obtained from microarray analysis, we also described biological networks modulated after fisetin and hesperetin treatment by KEGG and IPA analysis. Fisetin and hesperetin treatment showed a concentration-and time-dependent inhibition of proliferation and induced G2/M arrest for both agents and G0/G1 arrest for hesperetin at only the highest concentrations. There was a disruption of mitochondrial membrane potential together with increased caspase-3 activity. Furthermore, fisetin-and hesperetin-triggered apoptosis was confirmed by annexin V/PI analysis. The microarray gene profiling analysis revealed some important biological pathways including mitogen-activated protein kinases (MAPK) and inhibitor of DNA binding (ID) signaling pathways altered by fisetin and hesperetin treatment as well as gave a list of genes modulated ≥2-fold involved in cell proliferation, cell division, and apoptosis. Altogether, data suggested that fisetin and hesperetin have anticancer properties and deserve further investigation.

show abstract

“…TFPI2 is a Kunitz-type serine protease inhibitor with inhibitory activity against tumor growth and metastasis. 17 Analysis of lncRNA microarray data verified that TFPI2AS1 was overexpressed in human lung cancer tissues compared with matched non-tumor tissues. To explore TFPI2AS1 function in regulating the metastatic properties of NSCLC cells, the effects of TFPI2AS1 siRNA-mediated silencing and overexpression were assessed.…”

Section: Introductionmentioning

confidence: 90%

TFPI2AS1, a novel lncRNA that inhibits cell proliferation and migration in lung cancer

Gao

Lin

et al. 2017

Cell Cycle

View full text Add to dashboard Cite

Accumulating evidence demonstrates that a series of differentially expressed lncRNAs is important in tumorigenesis. However, the function of many of the lncRNAs in lung cancer remains elusive. In the present study, we used microarray analysis to identify lncRNAs that are dysregulated in non-small-cell lung cancer (NSCLC) as compared with normal tissues. Among the dysregulated lncRNAs, we identified TFPI2AS1, an antisense transcript of the tumor suppressor TFPI2 (tissue factor pathway inhibitor 2). TFPI2AS1 was shown to be markedly upregulated in NSCLC patient tumors as compared to paired non-tumor samples. TFPI2AS1 knockdown increased NSCLC cell proliferation and migration, which was associated with enhanced G1/S transition and downregulation of cyclin D1 and cyclin-dependent kinases 2 (CDK2), while TFPI2AS1 overexpression had the opposite effect. Knockdown and overexpression experiments also suggested that TFPI2AS1 regulates NSCLC cell migration and AKT activation. Moreover, TFPI2AS1 is a positive regulator of TFPI2. Our findings bring new insights for understanding the role of TFPI2AS1 in mediating the proliferation and migration of NSCLC cells by regulating TFPI2 expression.

show abstract

Beneficial role of overexpression of TFPI‐2 on tumour progression in human small cell lung cancer

Cited by 24 publications

References 71 publications

Establishment of a novel experimental model for muscle‐invasive bladder cancer using a dog bladder cancer organoid culture

Establishment of a novel experimental model for muscle‐invasive bladder cancer using a dog bladder cancer organoid culture

The pleiotropic effects of fisetin and hesperetin on human acute promyelocytic leukemia cells are mediated through apoptosis, cell cycle arrest, and alterations in signaling networks

TFPI2AS1, a novel lncRNA that inhibits cell proliferation and migration in lung cancer

Contact Info

Product

Resources

About